Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time-critical NHS settings
Multi-partner grant awarded for the validation of Genedrive® CYP2C19 ID Kit in time-critical NHS settings
ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is today pleased to announce that the evaluation agreement announced on 14 February 2022
The former leader of China’s Centre for Disease Control implies that an official investigation was carried out by Beijing into the Wuhan lab.
Genedrive plc (AIM: GDR), a leading provider of point-of-care molecular diagnostics, has announced that the UK’s National Institute for Health and Care Excellence (NICE) is advising in a draft guideline
Genedrive ® MT-RNR1 to commence roll out in Greater Manchester Project to follow NICE final recomendations scheduled for end of this month
Versarien plc (AIM: VRS), the advanced materials engineering group, announces that further to the announcement made on 10 March 2023, the Company confirms that Neill Ricketts’ resignation as Chief Executive
According to the Wall Street Journal, a recently updated and classified 2021 US Department of Energy study, provided to senior American lawmakers and the White House, suggests that the virus
Antibiotic Induced Hearing Loss test receives preliminary recommendation by NICE NICE enters public consultation phase of Early Value Assessment of the Genedrive® MT-RNR1 System
London, UK – ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women’s health, is pleased to announce today the signature of a lease for
Launch of Broker Offer to raise a maximum of £500,000
According to Carbon Tracker (a non-profit think tank), the world’s largest oil producers are spending billions on fossil fuel projects. These will be required if the world fails to meet